Nanobodies - The new concept in antibody engineering

African Journal of Biotechnology

Volumn 8, Issue 12, 2009, Pages 2645-2652

  Deffar, Khalissa ^a,b   Shi, Hengliang ^a   Li, Ang ^a   Wang, Xingzhi ^a   Zhu, Xiaojuan ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

^b FERHAT ABBAS UNIVERSITY   (Algeria)

Author keywords

Antibody engineering; Camelidae; Nanobodies; Nanoclone

Indexed keywords

NANOBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ANTIGEN BINDING; HEAVY CHAIN; LIGHT CHAIN; REVIEW; THERMOSTABILITY;

CAMELIDAE; LAMA GLAMA;

EID: 67650480902     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Ablynx (2005). www.ablynx.com. Nanobodies, pp. 1-2.
2. Ahmadvand D, Rahbarizadeh F, Khoddami Vishteh V (2008). High-Expression of Monoclonal Nanobodies Used in the Preparation of HRP-Conjugated Second Antibody. Hybridoma, 27: 269-276.
3. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997). Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414: 521-526. (Pubitemid 27390659)
4. Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, Muyldermans S, De Baetselier P (2006). Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat. Med. 12: 580-584.
5. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H (2004). Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64: 2853-2857. (Pubitemid 38500625)
6. Davies J, Riechmann L (1994). Camelising human antibody fragments: NMR studies on VH domains. FEBS Lett. 339: 285-290. (Pubitemid 24063464)
7. Deckers N, Saerens D, Kanobana K, Conrath K, Victor B, Wernery U, Vercruysse J, Muyldermans S, Dorny P (2008). Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. Int. J. Parasitol. pp. 1-9.
8. De Genst E, Saerens D, Muyldermans S, Conrath K (2006). Antibody repertoire development in camelids. Developmental and Comparative Immunol. 30: 187-198.
9. De Haard H (2008). Nanobodies-small is beautiful. Eur. Biotechnol. Sci. Ind. New, 7: 39-41.
10. HH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J. Biotechnol. 78: 11-21.
11. Hamers-Casterman C, Atanhouch T, Muyldermans S, Robinson G, Hamers C, Bajyana Songa E, Bendahman N, Hamers R (1993). Naturally occurring antibodies devoid of light chains. Nat. 363: 446-448. (Pubitemid 23179389)
12. Harmsen MM, De Haard HJ (2007). Properties, production and applications of camelid single-domain antibody fragments. Appl. Microbial. Biotechnol. 77: 13-22.
13. Hmila I, Ben Abdallah RBA, Saerensb D, Benlasfard Z, Conrathb K, El Ayeba M, Muyldermans S, Bouhaouala-Zahara B (2008). VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol. Immunol. 45: 3847-3856.
14. Holliger Ph, Hudson JP (2005). Engineering antibody fragments and the rise of single domains. Nat. Biotechnol. 23: 1126-1136.
15. 99mTc-Labeled EGFR-Specific Nanobody for In vivo Monitoring of EGFR Expression. Mol. Imaging Biol. 10: 167-175.
16. Joosten V, Roelofs MS, Van Den Dries N, Goosen T, Verrips CT, Van Den Hondel CAMJJ, Lokman BC (2005). Production of bifunctional proteins by Aspergillus awamori: Llama variable heavy chain antibody fragment (VHH) R9 coupled to Arthromyces ramosus peroxidase (ARP). J. Biotechnol. 120: 347-359.
17. Köhler G, Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nat. 256: 495-497.
18. Lam AY, Pardon E, Korotkov KV, Hol WGJ, Steyaert J (2009). Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterdimer from Vibrio vulnificus. In Press, J. Structural Biol. pp. 1-8.
19. Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB (2007). Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods, 324: 13-25. (Pubitemid 47001424)
20. Muyldermans S (2001). Single domain camel antibodies: current status. J. Biotechnol. 74: 277-302. (Pubitemid 34179619)
21. Muyldermans S, Baral TN, Cortez-Retamozzo V, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, Rothbauer U, Stijlemans B, Tillib S, Wernery U, Wyns L, Hassanzadeh-Ghassabeh Gh, Saerens D (2008). Camelid immunoglobulins and nanobody technology. In Press, Vet. Immunol. Immunopathol. pp. 1-6.
22. Pavlou AK, Beslsey MJ (2005). The therapeutic antibodies market to 2008. Eurpean J. Pharmaceutics Biopharmaceutics, 59: 389-396.
23. Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh AA (2006). Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol. Immunol. 43: 426-435. (Pubitemid 41740431)
24. Reichert J, Pavlou A (2004). Monoclonal antibodies market. Nat. 3: 383-384.
25. Revets H, De Baetselier P, Muyldermans S (2005). Nanobodies as novel agents for cancer therapy. Expert. opin. Biol. Theor. 5: 111-124.
26. Riechman L, Muyldermans S (1999). Single domain antibodies: comparison of camel VH and camelised human VH domains. J. Immunol, Methods, 231: 25-38.
27. Roitt IM, Delves PJ (2001). Roitt's essential immunology. In: Blackwell Publishing. Receptor localization. United Kingdom: Oxford. p. 37.
28. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, De Haard HJ, Van Bergen en Henegouwen PMP (2007). Efficient inhibition of EGFR signalling and of tumor growth by antagonistic anti-EGFR nanobodies. Caner Immunol. Immunother. 56: 303-317.
29. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, Backmann N, Conrath K, Muyldermans S, Cardoso MC, Leonhardt H (2006). Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat. Methods, 3: 887-889.
30. Roux KH, Greenberg AS, Green L, Strelets L, Avila. D, Mckinney EC, Flajnik MF (1998). Structural analysis of the nurse shark (new) antigen receptor (NAR): Molecular convergence of NAR and unusual mammalian immunoglobulins. Porc. Nalt. Acad. Sci. 95: 11804-11809.
31. Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, Conrath K (2004). Single-domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J. Biol. Chem. 279(10): 51965-51972.
32. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter Revets HPD, De Baetselier P, Muyldermans S, Magez S (2004). Efficient targeting of conserved cryptic epitopes of infectious agents by single-domain antibodies: African trypanosomes as paradigm. J. Biol. Chem. 279: 1256-1261.
33. Tanha J, Xu P, Chen Zh, Ni F, Kaplan H, Narang SA, MacKenzie CR (2001). Optimal design features of camelised human single-domain antibodies libraries. J. Biological Chem. 276: 24774-24780. (Pubitemid 37412948)
34. HH antibody fragments by Saccharomyces cerevisiae. Enzyme Microb. Technol. 30: 273-278.
35. Vaeck M (2004). The therapeutic potential of nanobodies. Drug discovery Innovations Pharmaceutical Technol. pp. 8-42.